Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA
30 Mars 2022 - 07:00PM
Oxurion has successfully raised EUR >10 million
from leading US and European healthcare investors in a private
equity placement and Negma Group has converted 240 convertible
bonds in Oxurion resulting in a EUR 600,000 capital increase (as
part of Negma Group’s EUR 30 million Capital Commitment1 that will
allow Oxurion to focus on progressing its novel and differentiated
back of the eye drug candidates that are targeting potential market
opportunities of over USD 12 billion).
Leuven, BE, Boston, MA,
US – March 30,
2022 –
07.00
PM CET – In accordance with
article 15 of the Belgian Act of May 2, 2007 on the disclosure of
major participations in issuers of which shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or
“Oxurion”), announces the below information, following (i) the
issuance of 7,226,039 new ordinary shares on March 7 (as listed on
March 7, with respect to 4,864,929 new ordinary shares and on March
21, with respect to 2,361,110 new ordinary shares) 2022, for a
total amount of EUR 10,405,500, as the result of the Company’s
capital increase in cash and (ii) the issuance of 500,000 new
ordinary shares on March 23 (as listed on March 29), 2022, for a
total amount of EUR 600,000, as the result of the conversion of 240
convertible bonds pursuant to the Capital Commitment entered into
with Negma Group.
Following completion of the capital increase in
cash and the capital increase through the conversion of the
convertible bonds, the total number of shares issued by Oxurion
amounts to 47,128,892 outstanding ordinary shares carrying voting
rights (compared to 39,402,853 outstanding ordinary shares
previously). This number will be used as the denominator for the
calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following
updated information:
|
67,931,161.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
47,128,892 |
- Total number of ordinary shares (=
denominator)
|
47,128,892 |
- Number of outstanding rights to
subscribe to securities carrying voting rights not yet issued:
|
|
- 760,750 subscription rights
(“SR’s”) issued on November 20, 2017, entitling their holders to
subscribe to a total number of 760,750 securities carrying voting
rights (all ordinary shares);
- 135,000 SR’s issued on December 23,
2020, entitling their holders to subscribe to a total number of
135,000 securities carrying voting rights (all ordinary
shares);
- 1,039,500 SR’s issued on April 14,
2021, entitling their holders to subscribe to a total number of
1,039,500 securities carrying voting rights (all ordinary
shares);
- 550,000 SR’s issued on September
22, 2021, entitling their holders to subscribe to a total number of
550,000 securities carrying voting rights (all ordinary
shares);
- 230 convertible bonds issued on
October 11, 2021, entitling their holder (Negma Group) to subscribe
to a total number of securities carrying voting rights (all
ordinary shares) in accordance with the terms and conditions set
forth in the Issuance and subscription agreement entered into
between the Company and Negma Group on August 26, 2021;
- 100 convertible bonds issued on
December 20, 2021, entitling their holders (Kreos Capital VI (UK)
Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax
Medison Finance (Cayman) L.P.) to subscribe to a total number of
securities carrying voting rights (all ordinary shares) in
accordance with the terms and conditions of these convertible bonds
as attached to the Agreement for the provision of a Loan Facility
entered into between the Company, Kreos Capital VI (UK) Limited,
Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance
(Cayman) L.P., on November 21, 2021; and
- 862,000 SR’s issued on December 30,
2021, entitling their holders to subscribe to a total number of
862,000 securities carrying voting rights (all ordinary
shares).
|
END
About
Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (wet AMD) and macular edema
following retinal vein occlusion (ME-RVO). Oxurion is aiming to
build a leading global franchise in the treatment of retinal
vascular disorders based on the successful development of its two
novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of DME patients showing suboptimal response to anti-VEGF
therapy. THR-687 is a highly selective pan-RGD integrin antagonist
that is being developed as a potential first line therapy for DME
patients as well as wet AMD and potentially ME-RVO. Oxurion is
headquartered in Leuven, Belgium, with corporate operations in
Boston, MA. More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NV Tom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michaël DillenChief Business
OfficerTel: +32 479 783 583michael.dillen@oxurion.com |
EU MEDiSTRAVA ConsultingDavid Dible/Sylvie Berrebi/Frazer HallTel:
+44 (0) 203 928 6900oxurion@medistrava.com USWestwicke, an ICR
companyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
1 Press release Oxurion, 06/04/2021
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024